Bafna Pharmaceuticals delivered a strong financial performance for FY26, reporting a net profit of ₹111.00 million, a 167% increase from ₹41.53 million in the previous year. The pharmaceutical manufacturer achieved this growth despite modest top-line expansion, highlighting improved operational efficiency and cost control measures implemented during the fiscal year.

Revenue from operations grew by 3.26% to ₹1,506.17 million from ₹1,458.57 million in FY25. Export sales were a key growth driver, surging 31.29% to ₹958.10 million. This export acceleration contributed significantly to the company's profitability, as international markets typically offer better pricing power compared to domestic segments.

Financial Performance Highlights

The company's EBITDA expanded by 48.74% to ₹207.04 million, pushing the EBITDA margin from 9.54% to 13.75%. This margin improvement indicates effective management of input costs and operational leverage. Earnings per share (EPS) more than doubled to ₹4.69 from ₹1.76 in the prior year.

What the Numbers Show

A critical observation from the financials is the divergence between revenue growth and profit growth. While revenue increased by only 3.26%, net profit surged by 167%. This suggests that the profit uplift was driven primarily by margin expansion rather than volume growth. Additionally, other income rose to ₹475.63 million from ₹274.22 million, contributing significantly to the bottom line. Investors should note that while operational efficiency improved, the high reliance on non-operating income components warrants monitoring in future quarters.

Operational Developments

Bafna Pharmaceuticals continued its strategic focus on capacity expansion and regulatory compliance. The company expanded its capsule manufacturing capacity from 375 million units to 600 million units during FY26. It also established a dedicated granulation facility at its Grantlyon plant in Chennai, enhancing manufacturing flexibility.

Key operational milestones included:

• Maintaining global accreditations including EU-GMP, UK-MHRA, TGA-Australia, and WHO-GMP.
• Registering 51 new products across various markets, including Australia, Philippines, and Nigeria.
• Hive-off of its Madhavaram manufacturing unit to focus on modernized core assets.

Credit Rating Upgrade

Reflecting improved financial health, ICRA revised Bafna Pharmaceuticals' credit outlook from stable to positive on January 23, 2026. The long-term credit facilities retained a BB+ rating, while short-term facilities maintained an A4+ rating. This upgrade underscores the company's strengthened balance sheet and debt servicing capability.

The Board did not declare any dividend for FY26. The 31st Annual General Meeting is scheduled for September 11, 2026, where shareholders will consider the adoption of audited financial statements and the re-appointment of directors.

Bafna Pharmaceuticals reported a sharp decline in profitability for the quarter ended June 30, 2026, as net profit fell to ₹7.51 lakh from ₹338.89 lakh in the corresponding period of the previous fiscal year. The Chennai-based pharmaceutical manufacturer saw its revenue from operations drop 23.2% year-on-year to ₹2,658.32 lakh, reflecting broader operational pressures. EBITDA contracted to 9M Rupees from 51M Rupees year-on-year, with the EBITDA margin compressing sharply to 3.31% from 14.64%, underscoring the severity of the margin erosion during the quarter. The Board of Directors approved the unaudited financial results on August 11, 2026, following a review by the Audit Committee.

The steep drop in earnings was driven by a combination of lower top-line performance and persistent cost structures. While total income decreased to ₹2,849.42 lakh from ₹3,521.96 lakh year-ago, total expenses remained relatively high at ₹2,841.91 lakh. This resulted in a pre-tax profit margin that compressed significantly compared to the prior year. The statutory auditors, Brahmayya & Co., issued a limited review report on the financial statements, confirming compliance with Ind AS 34 and SEBI regulations.

Financial Performance Highlights

The following table outlines the key financial metrics for the quarter ended June 30, 2026, compared to previous periods:

Revenue from operations declined to ₹2,658.32 lakh from ₹3,462.40 lakh in Q1FY26. The decline in total expenses of 10.7% was not sufficient to offset the larger revenue drop of 23.2%, leading to severe compression in both operating and net margins. Other income increased to ₹191.10 lakh from ₹59.56 lakh, providing some cushion but failing to prevent the bottom-line collapse.

What the Numbers Show

The divergence between the decline in revenue and the slower decline in expenses highlights fixed-cost rigidity within the business model. While cost of materials consumed dropped to ₹1,431.50 lakh from ₹1,755.78 lakh, employee benefit expenses remained nearly flat at ₹561.63 lakh compared to ₹563.99 lakh year-ago. This suggests that operational leverage is currently working against the company during periods of volume or value contraction. The EBITDA margin contraction from 14.64% to 3.31% year-on-year further illustrates how fixed and semi-fixed costs have disproportionately weighed on profitability as revenues declined. Additionally, finance costs decreased slightly to ₹93.70 lakh, indicating stable debt servicing obligations despite the revenue headwinds.

Regulatory and Legal Disclosures

The filing includes an emphasis of matter regarding ongoing Goods and Services Tax (GST) disputes. The company has received a demand order for ₹235.47 lakh and another order for the recovery of GST refunds amounting to ₹331.09 lakh, including interest and penalties. Bafna Pharmaceuticals has filed an appeal against the demand and obtained a stay on the refund recovery amount through a writ petition before the Madras High Court. Management stated it does not anticipate any adverse financial outcome from these proceedings.

Corporate Actions

The Board also scheduled the 31st Annual General Meeting (AGM) for September 11, 2026, to be held via Video Conferencing/Other Audio-Visual Means. The register of members will remain closed from September 5, 2026, to September 11, 2026, for the purpose of determining dividend entitlements and voting rights. The cut-off date for voting eligibility is set as September 4, 2026.